Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
tDCS as Adjunct to Varenicline for Smoking Cessation
NCT06798324Phase 4Recruiting
- Sponsor
- Center for Addiction and Mental Health
- Start
- Mar 2025
- Primary completion
- Jan 2028
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial (2 arms), sponsored by Center for Addiction and Mental Health. Primary endpoint: 30-Day Continuous Abstinence at End-Of-Treatment at Week 12. Started Mar 2025; status: recruiting.
Beyond the preview
Go deeper on NCT06798324.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06798324.